Fabtech Tech. (FABTECH)

FairStock Score: 11/100 — RISKY

Score breakdown: P/E: 0/3 · ROCE: 1/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Promoter holding of 68.94% keeps owner interests aligned with shareholders.
• Debt/equity of 0.22 is manageable, limiting balance sheet stress.
• ROCE of 21.98% shows the business was historically efficient at deploying capital.
• Healthcare research, analytics and technology sits in a sector with long-term structural growth potential.

Concerns

• Sales are down 39.84% and profit growth is -127.76%, with the latest quarter reporting a net loss of ₹6 crore.
• At ₹159, the stock trades at a P/E of 120.17 despite collapsing earnings — valuation is far too rich for current fundamentals.
• Piotroski F-Score of 3/9 signals weak financial health and a deteriorating operating position.
• Zero dividend yield means shareholders get no income while waiting for a recovery that is not yet visible.

AI Analysis

At ₹159, Fabtech Tech asks me to pay 120 times earnings for a business whose profits have fallen 127.76% and whose latest quarter delivered a ₹6 crore loss. That math makes no sense to me. Sales are down almost 40%; the company is shrinking, not compounding. A Piotroski score of 3/9 reinforces my suspicion that financial health is deteriorating. The balance sheet is not catastrophic — debt/equity is only 0.22 and ROCE is 21.98% — but a decent historical return on capital means little when current profitability has vanished. Book value of ₹60.17 provides some asset backing, yet at 2.64 times book I am not getting a margin of safety. Promoter holding of 68.94% is reassuring because owners remain heavily invested, but high ownership does not create an economic moat. There is no dividend to compensate me while I wait. Healthcare research, analytics and technology may have long-term opportunity, but this company's recent operating trajectory is dangerously negative. A FairStock score of 0/100 and an F-score of 3 are loud warning flags. I would need to see a clear path back to profitable growth, stable quarterly revenue, and evidence that the decline is a temporary setback rather than a permanent loss of competitive position. Until then, this is not a business I can value with confidence. In Graham's language, it fails the test of a defensive investment. I would rather miss the turnaround than risk permanent capital in a business whose earnings are moving in the wrong direction at such speed.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer